Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) - Related Studies

Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) (ROSORC)

This study has been completed.

Study NCT00609401 Information provided by Italian Trial in Medical Oncology

First Received on January 11, 2008. Last Updated on February 25, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Metastatic Disease
Renal Cell Carcinoma

Additional conditions recognized in this trial

Carcinoma
Carcinoma, Renal Cell
Neoplasm Metastasis

More general conditions related to this trial

Adenocarcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplastic Processes
Pathologic Processes
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms

Interventions listed in this trial

Nexavar (Sorafenib)
IL-2

Additional drug interventions recognized in this trial

Interleukin-2
Sorafenib

More general drug interventions related to this trial

Analgesics
Analgesics, Non-Narcotic
Antineoplastic Agents
Central Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Sensory System Agents
Therapeutic Uses

Sponsors listed in this trial

Italian Trial in Medical Oncology